chrisvoncsefalvay/vaers-outcomes huggingface dataset:
ADVERSE EVENT NOS (HAS TO SEE A CARDIOLOGIST AFTER GETTING THE BOOSTER); This spontaneous report received from a consumer via social media via a company representative concerned a female of unspecified age, race and ethnicity. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient was previously treated with covid-19 vaccine ad26. cov2. s (unspecified manufacturer) (dose number in series 1) (suspension for injection, route of admin, and batch number were not reported) dose, one total, start therapy date were not reported for prophylactic vaccination. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26. cov2.s.  The patient received covid-19 vaccine ad26.cov2.s (dose number in series 2) (suspension for injection, route of admin, and batch number were not reported) dose, one total start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, the patient experienced adverse event nos (has to see a cardiologist after getting the booster) (dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of adverse event nos (has to see a cardiologist after getting the booster) was not reported. This report was non-serious.
I had tachycardia that lasted three days. I than developed elevated systolic blood pressure.
Information has been received from a 66-year-old female with no pertinent medical history or allergies who on 30-OCT-2007 was vaccinated with a single dose of ZOSTAVAX (Oka/Merck).  Concomitant therapy included vitamins (unspecified).  On 02-NOV-2007 the patient experienced full blown rhinitis, upset stomach, mild diarrhea and flu like symptoms.  On 04-NOV-2007 the patient experienced a fever, earache and weakness.  The patient sought unspecified medical attention.  At the time of the report the patient's status was not recovered.  A product quality complaint was not involved.  No further information is available.
Patient came into office for evaluation 7 days after vaccine given, complains that the evening he got the vaccine he developed body aches, chills, diaphoretic spells, and fatigue. Symptoms were persisting.
Swelling of arm from above shoulder, down to elbow, beginning on 12/16 and continuing until 12/18. Was given prednisone, orally, for 3 days.
Breakthrough case after 3 vaccines Pfizer 4/9/21 lot# Ew0158;  Pfizer 4/30/21 lot# EW0179;  Pfizer 12/13/21 Lot# FD7218
Headache (4/10) and body aches (5/10) pain respectively began at about 18 hours after injection. Body and head aches, particularly joints and back, continue and have worsened at 30 hours out.   Mild-mod soreness at injection site (4/10)
from triage note: Cough and chest pain this morning with trouble breathing  01/29/2022. Denies fever. Second vaccine received Wednesday.
Information has been received from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. On or about 29-MAY-2012, the patient was vaccinated with ZOSTAVAX, (lot# and route unknown) as recommended for routine adult health maintenance for the long term prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster or shingles. On or about 06-FEB-2014, the patient was treated by a physician for the onset of severe vesicular rash, which was diagnosed as herpes zoster. The patient was prescribed famiciclovir and tramadol for management of her painful symptoms and chronic pain. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX, for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment.  As a further proximate result, the patient has suffered significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
5 days after vaccination, arm which had been sore when using, became painful while not in use also, requiring pain medication to sleep. Immobilized the 6th day so only one dose of pain meds to sleep last night and today (7th day) am continuing to baby it by hardly using it.
I tested positive for Covid-19 on April 2, 2023, I experienced fever of 103.0, chills, body aches, sneezing, runny nose, sore throat, I was prescribed PAXLOVID for my symptoms.
This case was reported by a healthcare professional via a sales representative and described the occurrence of swelling in a 5-year-old male subject who was vaccinated with KINRIX (GlaxoSmithKline). On 02 May 2011 the subject received unspecified dose of KINRIX at 0.5 ml in the left arm. On 05 May 2011, 3 days after vaccination with KINRIX, the subject experienced swelling, erythema and fever The events were indicated to be local injections site reactions. At the time of reporting the events were resolved. In the reporter's opinion, the events were probably related to treatment with KINRIX. Follow-up information was received on 14 June 2011. It was reported that the subject experienced a local reaction at the injection site the day following administration of KINRIX, on 03 May 2011. The reaction included swelling, erythema and fever. The events resolved by 10 May 2011. In the reporter's opinion, the events were probably related to treatment with KINRIX.
10/30/09 VAERS to be submitted per request. Client called 10/30/09 for another matter and stated had some nasal congestion. Nurse reassured congestion may occur with nasal flu mist. Call if sxs worsen or continue. 11/2/09
From telephone contact with manufacturer on 11/5/01 it was reported that a 10 week old female infant received an ActHIB, an IPOL and a Prevnar vaccination at 10:30am (date not specified). At 3:00pm the patient awoke from nap, the patient's mother reported both legs from waist to toes were purple. At 4:30pm when patient was seen in physician's office the symptoms resolved. This case is closed.
After vaccination, went home and laid on couch and slept for a few hours. When I awoke, I found myself on the floor. Tried to get up off the floor but could not. I crawled on the floor to the bathroom and took care of business. I managed to contact my neighbor with phone. Called MD for an appointment and saw another MD.
2nd flu vaccine dose was give one week too early (given at 3 weeks past the first dose). No reported reactions
Patient as a lively 80 year old who took the Pfizer booster (after having 2 Moderna vaccines in her vaccination series.) She had the booster on December 10 . She collapsed in her home on December 14, 2021,  and was found unconscious on December 15, 2021., by a family member. She never regained consciousness and died in an ambulance on the way to the hospital.  The cause of death was not really explained -- and she died very close in time  to her Covid booster shot.
Patient given an expired dose of Flumist. Dose expired on 1-10-08. Given on 01-23-08.
Vaccine gave him Myocarditis; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of MYOCARDITIS (Vaccine gave him Myocarditis) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Vaccine gave him Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Vaccine gave him Myocarditis) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   Concomitant medications was not provided by the reporter Treatment information was not provided.  Company Comment: This case concerns a patient of unknown age and gender with no relevant medical history  reportedwho experienced serious expected event of myocarditis. The event occurred after an unknown dose. Rechallenge was unknown due to lack of information regarding number of doses administered and reoccurrence of the event. The benefit-risk relationship of drug is not affected by this report; Sender's Comments: This case concerns a patient of unknown age and gender with no relevant medical history  reportedwho experienced serious expected event of myocarditis. The event occurred after an unknown dose. Rechallenge was unknown due to lack of information regarding number of doses administered and reoccurrence of the event. The benefit-risk relationship of drug is not affected by this report
Patient received the COVID-19 vaccine IM in her left arm at 1618. At 1638, she complained of tingling/numbness to her tongue and gums as well as her throat. She also developed marked nasal congestion. At 1644, that patient was administered an Epipen.  By 1646, her nasal congestion resolved and there was no progression of her tingling/numbness however these both lasted until transfer to ED by 1645 for close observation/follow-on therapy. Patients vital signs remained appropriate for interventions.
Information received on 07MAY2013 from a pharmaceutical company on behalf of a consumer who reported an adverse experienced via social media. A female experienced pain, causing difficulty in sleep, and decreased limb mobility following immunization with ANTHRAX vaccine. On an unspecified date, the female received dose 2 of ANTHRAX vaccine (site, route, lot number not reported). Reportedly, 36 hours after immunization the patient experienced pain in the arm that was keeping her awake. She reported that she could barely lift her arm. She stated that she had barely noticed the first dose of ANTHRAX vaccine, and questioned what she or the administrator had done differently for the 2nd dose. No further information was reported.
Patient Fall - she was treated for COPD exacerbation with steroids and that has significantly improved she is stiff she has been discharged on 3 L and she is chronically on 2.5 her acute on chronic hypercarbic hypoxemic respiratory failure i.e. hypoxia and hypercapnia improved throughout and she is on a tapering course of prednisone.  ED visit and hospital admission within 6 weeks of receiving the COVID vaccine.
A non-serious spontaneous report of accidental exposure and sore throat has been received from a MedImmune representative concerning an adult female. Medical history and concomitant medications were not reported. On an unspecified date last year, the reporter stated a nurse reported after each flu clinic with FLUMIST last year, the nurse experienced a sore throat for a day. The events accidental exposure during administration and sore throat resolved.
Narrative:  Patient completed Moderna COVID series in February 2021 and residing in Nursing Home. Had congestion and low O2 sat. Taken to hospital and tested positive for COVID-19 on 8/22/21 but not admitted. Sent back to nursing facility with oral dexamethasone and required more oxygen. Admitted to hospital 8/23 and treated with remdesivir, dexamethasone, and enoxaparin. Discharged back to nursing home 8/26/21.
Initially itchy rash began on 12/25/2020 treated with antihistamine with fair effect. Dry rash, almost with welt presentation, persists to date, however is no longer itchy.   Painful bumps legs first noticed on 1/4/2021. Painful raised bumps were red and inflamed, initially on R calf however then appearing on bilateral shins. Painful bumps persisted until 1/11/2021, when they then progressed to bruises. Per Medical team in ED and PCP visit, thought to be erythema nodosum. Treated with 600 mg Advil and Zyrtec with good effect. Fully resolved by 1/16/2021.
This is a 71y.o. male with past medical history significant for CAD, DVT, orthostatic hypotension, depression, s/p pacemaker placement for bradycardia, and possible bipolar who presents to the emergency department with chief complaint of shortness of breath.  Patient states that he has had this progressive shortness of breath for 1 month now.  He states now that he is having exertional dyspnea as well as conversational dyspnea.  He states that now he can only walk about 10 feet without having to rest.  He is also noticing the same time.  His legs have become significantly more swollen than previous.  He states that he does have orthopnea.  He states he came in because his PCP found that his D-dimer was 1300 and was worried about a recurrent DVT and possible PE.  The patient is currently on Eliquis 5 mg twice daily.  Patient states that his wife does have the coronavirus and that he has felt like he has had rhinorrhea.  Patient is fully vaccinated.  He denies any chest pain, nausea, or abdominal pain.   ED vitals: Blood pressure 207/93, heart rate 107, SPO2 97% on 3 L of oxygen.  Patient was then given 10 mg of hydralazine with blood systolic down to 180.  He was then given his home dose of Coreg.  Labs significant for a potassium of 5.7 which was treated medically.  D-dimer of 1093, BNP of 3828.  Troponins of 0.04x2.  The patient is coronavirus positive.   CTA PE protocol: No evidence of pulmonary embolism, mild cardiomegaly with moderate right and small left pleural effusion.  Nonobstructing right renal calculus
myocarditis - severe burning chest pain that lasted several hours.  This is in addition to fatigue, fever, chills, and  perspiration.
Systemic: Confusion-Medium, Systemic: Fainting / Unresponsive-Medium, Additional Details: pt was with dad he said she just went blank and passed out off the chair she never stopped breathing but lost consciousness we kept her comfortable until paramedics came
Patient woke up in the middle of the night 4-5 days post vaccination (first dose) around 12-12:30am. Chief complaint: mucus in eyes, sinus pain, sores in mouth, pruritis on trunk/breast/underarm, heart palpitations. Patient took Tylenol at 1 am and was completely resolved by 2:30am same night. Patient unable to attribute symptoms to any other cause.
Swore arm at injection site and serious fatigue  at ten pm after shot that continued through the following day and evening until feeling better on Wednesday morning after 12 hours of sleep!  Also I noted that the 2nd covid-19 dose recorded on the15th of March is identical to the one I received  on February 22, 2021, leading me to believe that the person who administrated the second shot simply copied the lot number information from the first shot that was recorded on card.
Vomiting, vertigo, hives, crushing pain in lung and back area during 36 hours after the 2nd booster. Transient Global Amnesia episode on 6.20.2022.  Went to the ER at approximately 7:15 pm. Admitted at approximately 1:30 am on 6.21.2022.
Pregnant and received 1st dose in March 2021/received 2nd dose 10Aug20221; 1st dose in March 2021/received 2nd dose 10Aug20221; This spontaneous prospective pregnancy case was reported by a physician and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnant and received 1st dose in March 2021/received 2nd dose 10Aug20221) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose in March 2021/received 2nd dose 10Aug20221) in a 23-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by reporter.  No concomitant medication reported.    In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 09-Feb-2021 and the estimated date of delivery was 16-Nov-2021. On 10-Aug-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose in March 2021/received 2nd dose 10Aug20221). On an unknown date, the patient experienced EXPOSURE DURING PREGNANCY (Pregnant and received 1st dose in March 2021/received 2nd dose 10Aug20221). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  second week of the pregnancy.  On 10-Aug-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose in March 2021/received 2nd dose 10Aug20221) had resolved. At the time of the report, EXPOSURE DURING PREGNANCY (Pregnant and received 1st dose in March 2021/received 2nd dose 10Aug20221) outcome was unknown.       For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication reported.  No treatment medication reported.   Reporter did not allow further contact
eye condition broken blood vessel in the eye; A spontaneous report was received from a consumer concerning herself, a female patient of unknown age who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced eye condition broken blood vessel in the eye/ Eye haemorrhage,  The patient's medical history was not provided. Concomitant product use was not provided by the reporter.  On 27Feb2021, prior to the onset of the event the patient received the first of two planned doses of mRNA-1273 (lot/batch: Unknown) via Intramuscular route for prophylaxis of COVID-19 infection.  On an unknown date, patient experienced eye condition broken blood vessel in the eye and was considered as medically significant.  Action taken with mRNA-1273 in response to the event was Unknown.   The outcome of event eye condition broken blood vessel in the eye was unknown, at the time of this report.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Rash, UrticariaPruritus, all over rash, torso, arms, upper legs. Narrative:
OBSTRUCTIVE SLEEP APNEA 10/31/2022 OSTEOARTHRITIS OF LEFT HIP
2"x3" reddened rash to right Deltoid area; erythema and warmth present. Acetaminophen given for pain
Woke up after 3 hours of sleep with very bad migraine, nauseous, dizzy, threw up around half an hour after waking up. Had no energy for around 5 hours, had a fever, and a bad migraine. After taking Tylenol and Compazine symptoms got better all afternoon, then the nausea and dizziness returned around 10pm. Threw up again.
c/o numbness under left eye & on left side of face & teeth one hour after receiving vaccine.  Vision in left eye "seems blurry".  No other symptoms - referred to personal physician.  Reported to work next day (school employee).  States MD said she had a chemical reaction to vaccine.
red wheel apprx 3" immediately after receiving V2V- wheel baded after 24 hrs after 24 hrs - 3 days after a red/blue discoloration.
Axillary adenopathy 1 day after HPV occurred after HPV #1 and HPV #2 (Large tender axillary node) on side of injection.
10/26 - HOT TO THE TOUCH, SEVERE BODY ACHES, CHILLS, SEVERE INTENSE HEADACHE, HIVE RASH THAT'S GROWING IN DIAMETER ,  10/27 - HOT TO THE TOUCH, SEVERE BODY ACHES, CHILLS, SEVERE INTENSE HEADACHE, HIVE RASH THAT'S GROWING IN DIAMETER ,  DIARREA, ABDOMINAL CRAMPING
pt presents to ED with c/o weakness and chest pain, N/V, SOB, chronic cough; positive COVID test; treated with steroids, ABX, anticoagulant, remdesivir; pt had abnormal LFTs, choledocholithiasis, type 2 MI, severe chronic cardiomyopathy; responded well to COVID tx; pt declined ERCP; pt decided on DNR; renal function worsened; admitted to ICU; pt's condition worsened and he passed away in the hospital
Broke out in red blotchy areas over face and forehead.  Legs also had some redness.  Red areas were not raised.  No respiratory symptoms.   Redness was gone by 11:30 AM.
Nosebleed; This spontaneous case was reported by a consumer and describes the occurrence of EPISTAXIS (Nosebleed) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history were reported. .     On 26-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Jul-2021, the patient experienced EPISTAXIS (Nosebleed). At the time of the report, EPISTAXIS (Nosebleed) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient reported experiencing nosebleed on 28-Jul-2021 and again on 30-Jul-2021.  No Concomitant medication were reported.  No treatment medication were reported.
pt stated when she woke up the morning after the shingrix vaccine she was tired. went back to sleep and woke up even more tired. she somehow ended up on the floor and couldn't get up. family came to her door and had to break it in because she couldn't get to the door. went to the hospital and was transferred to a rehab facility for 2 weeks. muscle weakness was so bad she needed therapy. she said it also affected her heart muscle.
patient complained of fatigue and nausea x3, last chemo 4/8/2021, felt fatigued and spent most of time in bed, on 4/18 developed more nausea and vomited x1, when admitted to EC, HR was 120-130s with normal BP, CT showed concern for rectal perforation with fistula to right ovary, SBO, possible closed loop obstruction of small bowel with bowel ischemia and free air, patient taken to OR for emergent ex lap, colostomy, currently still admitted to hospital
This spontaneous report as received from a pharmacist refers to a patient of unknown age and demographics. Patient's medical history and drug reactions or allergies were not reported. On 21-AUG-2014 the patient was intramuscularly vaccinated with expired dose of PNEUMOVAX23 (dose: 0.5ml, lot #J009827, expiration date: 10-AUG-2014, anatomical location not provided). Concomitant medications were not reported. No adverse effect reported. The pharmacist also stated that there was a second patient who received an expired dose of PNEUMOVAX23 (lot # J009827, expiration date 10-AUG-2014; 0.5 ml, intramuscular, anatomical location not provided) on the same day (21-AUG-2014). This case is linked to MARRS#1408USA012807 via the same reporter link. Additional information has been requested.
shoulder soreness; diminished range of motion; injection site pain; This case was reported by a nurse via call center representative and described the occurrence of injection site pain in a 38-year-old female patient who received Flu Seasonal QIV Dresden (Fluarix Quadrivalent 2019-2020 season) (batch number BP959, expiry date 30th June 2020) for prophylaxis.   On 14th October 2019, the patient received Fluarix Quadrivalent 2019-2020 season (intramuscular). On 14th October 2019, less than a day after receiving Fluarix Quadrivalent 2019-2020 season, the patient experienced injection site pain. On 14th November 2019, the patient experienced shoulder soreness and joint range of motion decreased. On an unknown date, the outcome of the injection site pain, shoulder soreness and joint range of motion decreased were unknown.   It was unknown if the reporter considered the injection site pain, shoulder soreness and joint range of motion decreased to be related to Fluarix Quadrivalent 2019-2020 season.  Additional details were provided as follows: The patient received Fluarix Quadrivalent 2019-2020 season on left arm. The patient experienced pain at the injection site the same day.  Over an unspecified period of time, the patient began to experience a sore shoulder and a diminished range of motion described as difficulty moving the arm and putting on a shirt. The reporter consented to follow up.